December 25, 2020

To
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip Code- 532523

To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050

Scrip Symbol- Biocon

Dear Sir/Madam,

Subject: Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020

Please find below the “Company Statement” on the subject matter.

“This is to inform you that Biocon Biologics Limited, (a subsidiary of Biocon Limited) and Mylan (a subsidiary of Viatris Inc.) have been informed by the U.S. Food and Drug Administration (FDA) of a deferred action on the Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (bevacizumab).

To complete the application, the Agency noted that an inspection of the manufacturing facility is required as a part of the standard review process. However, due to restrictions on travel related to COVID-19, the Agency is unable to conduct an inspection during the current review cycle. We await the dates for the inspection.

There are no additional observations related to the application.” Company Spokesperson, Biocon Biologics

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer